Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

The focus is on a drug called Lepodisiran, that could target certain factors that increase risk of heart attacks and strokes.

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Revolutionary drug Lepodisiran dramatically lowers Lp(a) cholesterol, a major heart attack risk factor. Learn about this ...

Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

This new research confirmed earlier findings showing that the experimental drug — lepodisiran, made by Eli Lilly, who funded the study — can "silence" the main gene responsible for ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Lepodisiran targets “elevated lipoprotein(a)” — also known as Lp(a) — which is a genetically inherited cardiovascular risk factor that affects about 20% of Americans. And about a quarter ...